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Plain English summary
Patients with rare diseases often help to develop new treatments for their conditions.
But once developed, those treatments are sometimes priced too high for many
patients to access them. We became aware that this is a problem in the course
of a social science research project that examines the place of rare diseases in
health policy. We therefore organized a two-day workshop to try and understand why
this problem occurs and what might be done about it.
The people who participated in our workshop were: representatives of rare disease
patient organizations, experts in matters of drug regulation and assessment of new
health technologies, consultants involved with companies producing treatments for
rare diseases, and social scientists researching related issues.
The main conclusions to emerge from the discussions were as follows:
Problems of access to treatments for rare diseases are not just due to high prices;
procedures for regulating, assessing and delivering new treatments also need to be
better organized. Patients and patient organizations have much to contribute to
this process. However, their resources are often very limited. Consequently, more
needs to be done to help them use those resources as effectively as possible. In
particular, regulators and healthcare providers need to ensure that their procedures
are clear and efficiently managed, so as not to waste patient organizations’ time
and money. Clearer guidance is needed on what patient organizations can do to
provide evidence of the effectiveness of new drugs. Insights gained in tackling rare
diseases might also be applicable to common disorders. Finally, the consequences
of Brexit for UK policies on rare diseases urgently need to be assessed.
Abstract
Since the enactment of orphan drug legislation in the USA, Europe and several
other countries, an increasing number of treatments for rare diseases have been
developed and many of them been approved for marketing. However, such
treatments tend to be priced very high, and access to effective treatments
remains a major challenge for patients with rare diseases – despite active
involvement of patients and their support organizations in various stages of
basic and applied research and commercial development. In order to allow
patients to benefit from treatments proved effective for their diseases, we need
(Continued on next page)
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to better understand why this challenge persists, and what steps might be taken
to address it. To that end, we organized a policy-engagement workshop, bringing
together individuals and organizations with direct experience of trying to secure access
to a treatment for a rare disease along with individuals with relevant expertise in
regulatory and commissioning processes for new medicines. With additional input from
social scientists who offered different perspectives on the value of patient involvement,
the workshop aimed to initiate a dialogue among the participants about how to
address the challenge in a sustainable manner. Discussions at the workshop stressed
that active involvement of patients is as valuable in the regulatory and commissioning
processes as in the research and development of new medicines. However, it also
highlighted certain risks and costs associated with such involvement. These include the
costs of adjusting to abrupt changes in regulatory and commissioning processes, and
the risk of being perceived as too close to commercial interests. To optimize use of
scarce resources and ensure continuing active involvement, such risks and costs need
to be better managed. Participants also noted that, owing to advances in genomic
technologies, common diseases are also becoming divided into rare sub-categories,
which are equally eligible for orphan drug designation. Consequently, involvement of
wider patient communities beyond rare disease communities will be critical for
continuing discussions about patients’ involvement in regulatory and commissioning
processes, and to consider how patients and their support organizations can best work
with other stakeholders – including companies, regulators and policymakers – to ensure
access to effective medicines.
Keywords: Rare diseases, Orphan drugs, Patient organizations, Partnership, Drug
development
Background
Rare diseases are one of the areas of medicine in which patient involvement and en-
gagement has become most deeply entrenched, in relation both to research and devel-
opment and to policymaking and health service delivery. This involvement has evolved
over time. The role of patient organizations in rare disease research used to be primar-
ily auxiliary – financially supporting work led by medical professionals, or donating
specimens required for undertaking such work. However, some rare disease patient or-
ganizations have recently been successful in assuming a more active role as partners to
the professionals, shaping research agendas and study designs to reflect their own per-
spectives [1, 2]. When an international consortium for rare diseases research was
launched in 2011 with the goals of developing new means of diagnosis and therapies
for the diseases, it adopted a policy that research on rare diseases should involve pa-
tients and/or representatives of patient organizations in all relevant aspects of the work
[3]. Their involvement is considered to be critical because patients and their carers pos-
sess different kinds of knowledge of their conditions from that of the professionals [4].
Involvement of rare disease patients and their families has been particularly success-
ful, in part because of the unique challenges that they face due to the rarity of their dis-
eases. In the past, many felt that that rarity led to scientists and policymakers paying
too little attention to their diseases. However, the situation started to change when pa-
tients’ advocacy efforts and close working with legislators resulted in the passage of the
Orphan Drug Act of 1983 in the United States [5, 6]. When consideration of similar le-
gislation in Europe took off in the mid-1990s, medical professionals and policymakers
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sought to actively involve patient organizations in the process, which led to enactment
of the EC Regulation on Orphan Medicinal Products in 2000 [7]. This Regulation estab-
lished, at the European Medicines Agency (EMA), the Committee for Orphan Medi-
cinal Products (COMP) – a body responsible for conferring orphan drugs designation
on products intended for diagnosis, prevention, or treatment of any life-threatening or
seriously debilitating disease or condition which affects no more than 5 in 10,000
people in the European Union. The Regulation also specified that the Committee
should include three representatives of patient organizations as full members [8, 9].
Reflecting on the important roles that rare disease patient organizations have played in
promoting policies and advancing biomedical sciences since the late twentieth century,
some medical professionals consider them to be “among the most empowered groups
in the health sector,” suggesting that their work can be a model for other organizations
that seek better diagnostics and treatments for their diseases [10].
The active engagement of patients with rare diseases and their support organizations
is now considered valuable in the commercial domain too. In the early 2010s, some
families and patient organizations sought to realize that value by involving themselves
directly in developing orphan drugs – in one case by founding a start-up company to
develop a promising line of treatment, in another by initiating clinical trials of a drug
that has shown some evidence of efficacy [11, 12]. More generally, because the low in-
cidence of rare diseases often makes it difficult to collect clinical evidence by conven-
tional means, such as randomized controlled trials, the EMA and COMP now
encourage companies developing orphan drugs to engage with patients as early as pos-
sible so as to adequately address the unmet medical needs from the patients’ viewpoint
[9]. Such involvement is often invaluable in helping companies secure approval of their
products, as patients can advise on practicable means of collecting clinical data, advise
on relevant criteria of clinical efficacy, and represent the human aspect of their condi-
tion to regulators.
Despite this active involvement in research and policy, however, rare disease patients
often face serious challenges in securing access to treatments for their conditions. Or-
phan drug legislation in the United States, Europe and a few other countries offers in-
centives for companies to develop drugs for rare diseases, and has successfully
increased the number of such drugs available on the market [13, 14]. However, manu-
facturers often charge very high prices for such drugs. Consequently, according to one
analysis, most orphan drugs would fail to meet the standard cost-benefit criteria
employed in health technology assessment (HTA) [15], and payers – be they private in-
surance companies or national health services – commonly question their affordability.
In some cases, patients have been granted access to a treatment on an ad hoc basis –
for example, an arrangement at the National Health Service (NHS) in the United Kingdom
for an enzyme replacement therapy for Gaucher disease – but the social and ethical accept-
ability of meeting such costs through special arrangements at the expense of treatments for
other conditions has been a subject of heated debate [16, 17]. Consequently, patients with
seriously debilitating or life-threatening conditions may go untreated even though effective
treatments are available. The situation is likely to become increasingly common in the fu-
ture, as treatments are found for a growing number of rare diseases, of which more than
7000 are currently known. It will also apply increasingly to common disorders such as can-
cer, as they become subdivided into rare sub-categories that qualify for inclusion under
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orphan drug legislation. A means of ensuring access to such treatments, while avoiding un-
sustainable increase in public expenditure on health services, and without exacerbating the
divide between those who can and cannot afford them, is therefore urgently needed [18].
The role of patients and patient organizations in developing such an approach will be
crucial.
Method
In order to better understand the reasons underlying the problem of access to treatments
for rare diseases, and to consider what steps might be taken to address that problem, the
authors organized a two-day workshop entitled Rare Diseases, Patient-Private Partner-
ship, and Access to Treatments at the University of Edinburgh in June 2016.
The workshop was organized as part of the Wellcome Trust-funded research project
Making Genomic Medicine, which aims to engage critically with key issues in modern
medicine by undertaking socio-historical investigations into the development of med-
ical genetics and genomic medicine. One such development that the project is studying
is the increased prominence of rare diseases in medical research and health policy. The
workshop was prompted in part by the interactions that one of the authors (KM) had
with rare disease patients, representatives of rare disease organizations, and others who
in one way or another have been trying to address the problem of access described
above, and in part by the realization that this is a major policy issue which will have im-
plications not just for a growing range of rare diseases, but for the sustainability of
health systems more generally.
The workshop was designed as a policy-engagement workshop, following a model de-
veloped by the Genomics Policy and Research Forum – an experimental initiative to
explore the intersections of genomic science and society, which was funded by the UK
Economics and Social Research Council between 2004 and 2013 [19]. It should not be
confused with a public engagement workshop. Typically, public engagement workshops
involve engaging with a representative or otherwise salient segment of the public in
order to ensure that their views, concerns, and critiques on a selected theme are taken
into account in the development of research, service provision or policy. By contrast,
the policy-engagement workshop model aims to bring together a group of stakeholders
from a range of relevant sectors, including but by no means confined to relevant ‘pub-
lics’, and to provide them with a ‘safe space’ in which to start a constructive dialogue on
an emerging or otherwise unresolved matter of policy. The purpose of the discussion is
to try to develop a shared understanding of the problem at hand, and to identify ways
in which different stakeholders might continue to work together to address that prob-
lem [20]. In effect, policy-engagement workshops are intended to encourage and initi-
ate the kind of ‘collective puzzling’ that often underlies successful policy development,
and to define and frame issues around which wider collective discussion and action
might usefully be conducted [21]. As such, we find that they work best in exploring is-
sues that have not yet attracted much notice from policy makers or other concerned
groups – as for instance the workshop reported here – and are far less effective as a
means of resolving established matters of disagreement. To ensure that dialogue pro-
ceeds as constructively as possible, the number of participants is usually small (experi-
ence suggests around 20–25 as a practical maximum), and participants are selected to
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ensure that relevant viewpoints are represented while as far as possible avoiding indi-
viduals known to be dogmatic or confrontational in their behaviour.
The workshop discussed here accordingly brought together representatives of rare
disease patient organizations with other stakeholders with experience of policy, regula-
tory and commercial activities around access to treatments for rare diseases. Some of
the participants were themselves rare disease patients or parents of children with rare
diseases, but that was not a positive selection criterion so much as a reflection of the
social make-up of the rare disease field itself. Participants – mainly but not solely from
the UK – were selected and invited to represent a broad range of perspectives and ex-
perience of relevant issues; where appropriate, they participated in a personal capacity,
representing their own personal understanding rather than the views of the organiza-
tions for which they worked or had worked. The planning and organization of the
workshop was led by the authors, who are both social scientists by training with no
personal stake in the issues to be discussed, beyond their academic interest in the med-
ical and policy problems of rare diseases. In selecting participants to invite, the orga-
nizers drew on their own knowledge of the field to identify individuals with relevant
knowledge and experience. We also drew on the expertise and experience of members
of the advisory committee to the Making Genomic Medicine project, in particular Alas-
tair Kent, then director of the Genetic Alliance UK and chair of the national multi-
stakeholder campaign Rare Diseases UK, and John Purves, former officer of the EMA.
In some instances, participants were also suggested by invitees who were themselves
unable to attend.
In selecting workshop participants, we made a deliberate decision not to include rep-
resentatives of patient organizations for cancer, though a growing number of orphan
drugs have been developed for rare forms of cancer, and patients are likely to encounter
similar problems of access to innovative treatments. Historically, however, scientific
and medical understanding of rare cancers, the politics of medical research and health-
care provision for cancer, and the formation of rare cancer patient organizations, have
all followed very different trajectories from the group of conditions more usually
regarded as “rare diseases”. In the interests of keeping the topic of discussion within
manageable bounds, we therefore decided not to address rare cancers – though there is
undoubtedly much to be gained from bringing the two communities into closer corres-
pondence in future.
Even while confining ourselves to rare diseases as usually understood, we were con-
scious that rare disease organizations vary enormously in size, resources, and aims, and
hold disparate ideas about whether and how best to partner with one another and with
researchers, healthcare providers, policy makers and pharmaceutical companies. We
therefore took care to invite participants from a range of organizations of different
styles and sizes. Nonetheless, the authors were acutely aware that limiting participation
to a small number of pre-selected invitees and excluding certain sectors meant that the
kinds of perspectives and experiences represented would inevitably be partial. However,
the aim of the workshop was not to ensure that all relevant voices and publics were
represented, but rather to initiate a constructive process of dialogue and reflection
among key stakeholders that would raising salient issues, demonstrate the value of en-
gagement in doing so, and thus contribute to longer-term and more inclusive processes
of policy formation. To that end, invitees were sent a short briefing document outlining
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the key policy issues as understood by the organizers, but discussion at the workshop
itself was deliberately kept as open-ended and exploratory and dialogical as possible,
and took place under the Chatham House Rule – that is, with agreement that while the
views expressed at the meeting might be reported, they would not be attributed to par-
ticular participants – so that participants would feel free to speak frankly [22]. In
addition, a small number of social scientists working in relevant areas were also invited,
whose task was to offer perspectives that might help participants to step back from
their own engaged experience and to appreciate it in the larger social and institutional
context within which they operate. (For a list of the workshop delegates, see Table 1).
The workshop consisted of four sessions. The first three sessions followed the same
format, starting with short presentations from selected delegates and then moving on
to open discussion. But each session had a different focus: the first session entitled
‘Costs and Benefits of Partnership’ explored the experiences of rare disease patient or-
ganizations and their views on the challenges and opportunities in partnering with
other stakeholders; the second ‘Rethinking Partnership’ looked at the social science per-
spectives on the types of social contract between ‘the studying’ and ‘the studied’; and
the third ‘Current Terms of Partnership’ examined the intersections of patients and
companies and ways of avoiding or minimizing potential conflicts of interest. The final
session then aimed to reflect on the outcomes of the preceding sessions, with opening
comments from four of the participants followed by general discussion.
The present report was then drafted by the authors, based on copies of the presenta-
tions, and notes and audio recordings of the discussions. The main purpose of the re-
port was to capture and publicize the key conclusions to have emerged from those
discussions, with the purpose of stimulating and informing further policy action around
access to medicines for rare and other diseases. The draft report was circulated for
comment to all the participants, and revised in light of their feedback, so as to ensure
that the issues presented here adequately reflect the discussion rather than the aca-
demic interests of the authors. All participants agreed that the results section of this
paper was a satisfactory representation of the main substance of the workshop conver-
sations. Additionally, consent to publish a full list of delegates was obtained from all
the participants; while this is not always the case for meetings held under the Chatham
House Rule, we felt that it would enable readers to better appreciate what viewpoints
and interests were represented and voiced in the workshop.
Results
Although the conversation at the workshop inevitably ranged beyond the specific ques-
tion of patient-company partnerships and their implications for access, discussion con-
centrated around the six key sets of issues presented in this section. Participants did
not necessarily agree on how to address these issues – on the contrary, some topics
were important precisely because they provoked disagreement – but all are clearly is-
sues around which further discussion or action is required.
1. The cost of drugs is important but not the only problem
Problems of access to treatments for rare diseases are generally attributed to their high
price. While this may be true for some innovative medicines, including enzyme replace-
ment therapy and gene therapy, other problems can also be identified. In particular,
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patients with some rare conditions might also benefit from cheaper drugs already avail-
able on the market for other indications. However, such drugs may still need to over-
come regulatory obstacles, often involving substantial delays, before they are made
available to patients with rare diseases. While such drugs may be available off-label, cli-
nicians or health care providers may be unwilling to use them in such circumstances
because of potential liability risk, leaving patients without access to them.
This is not to suggest that the cost is not also a problem; on the contrary, the high
price of some innovative medicines, and the fact that some patients may have to
Table 1 List of delegates (in alphabetical order)
Name Relevance to the topic
Campbell, Jean Founding member of Professional Patient Advocates in Life Sciences, a non-profit
organization in the United States to support patient-advocacy professionals in
pharmaceutical and biotechnology companies.
Greene, Lesley Founder of Children Living with Inherited Metabolic Diseases (CLIMB), founding
member of EURORDIS, and currently a patient-representative member (2009-)
and vice chair of COMP (2012-).
Hayden, Cori Professor of Anthropology at the University of California Berkeley, with research
interest in benefit-sharing arrangements in biosciences.
Kent, Alastair Director of Genetic Alliance UK and chair of Rare Diseases UK, which is a multi-
stakeholder campaign in the United Kingdom for patients with rare diseases and
all who support them.
Livingston, Heidi Public Involvement Advisor at the National Institute for Health and Clinical
Excellence (NICE) (participated in a personal capacity as an expert in patient
involvement in technology appraisal processes).
Meadowcroft, Robert Chief executive of Muscular Dystrophy UK, a charity organization supporting
individuals affected by muscle-waisting conditions in the United Kingdom.
Mikami, Koichi Research fellow in Making Genomic Medicine at the University of Edinburgh and
co-organizer of the workshop.
Moreira, Tiago Reader at Durham University with research interest in the roles of patient
organizations in the organization of health care and governance of biomedicine.
Parker, Samantha Head of Patient and Policy Affairs at biotechnology company Lysogene in France.
Pavelin, Colin Head of Regenerative Medicine and Rare Disease Policy at the UK Department of
Health (participating in a personal capacity as an expert in national policies on rare
diseases in the UK).
Purves, John Former head of the Quality of Medicines sector at the European Medicines Agency,
and an honorary fellow of the Innogen Centre at the University of Edinburgh.
Roberts, Charlotte Communications Officer of the MPS Society, a charitable organization supporting
individuals, families and professionals affected by mucopolysaccharide and related
diseases throughout the United Kingdom.
Schoneveld van der Linde,
Maryze
Former board member of the International Pompe Association, and a founder of
consultant company Patient Centered Solutions in the Netherlands.
Spink, Jayne Chief Executive Officer of the Tuberous Sclerosis Association, a charity supporting
individuals affected by tuberous sclerosis complex and their families and carers in
the United Kingdom and funding research.
Spring, Rachel Theme Coordinator at the National Institute for Health Research’s Rare Diseases
Translational Research Collaboration
Sturdy, Steve Professor of the Sociology of Medical Knowledge at the University of Edinburgh,
principal investigator of the Making Genomic Medicine project, and co-organizer
of the workshop.
Timmis, Oliver Chief Executive Officer of the AKU Society, a charity organization supporting
individuals affected by alkaptonuria in the United Kingdom that initiated a
EU-funded consortium called DevelopAKUre program.
Upadhyaya, Sheela Associate Director of Highly Specialised Technology program at the National
Institute for Health and Clinical Excellence (participated in personal capacity
as an expert in evaluation of medicines for rare diseases).
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depend on them throughout their lives, causes considerable concern for both patients
and healthcare providers, and can sometimes be a problem for suppliers in the long
term too. In some countries, including the United States, suppliers offer subsidies to
patients who cannot afford their drugs through patient support or free access pro-
grams. However, the cost of offering such programs may be recovered by raising the
price of the drugs for paying patients and providers. Furthermore, some companies take
advantage of orphan drug legislation by taking existing medicines through the path laid
out for orphan drug development, re-branding them as drugs for rare diseases and,
once designated as orphan drugs, marketing them at an elevated price. One way of ad-
dressing this issue would be to institute a system to ensure transparency of the cost of
production and fair pricing – although we were made aware that this issue is an ex-
tremely sensitive area in practice and hence any effort to introduce such a system
would require careful planning and consultation with relevant stakeholders.
2. Clearer and simpler regulatory and assessment processes for orphan drugs
are needed
The complexity of regulatory and HTA procedures was identified as a possible major
reason why rare disease patients often face prolonged delays before drugs of proven ef-
ficacy become available. In Europe, all orphan drugs have to be approved first by the
EMA, then through a different HTA system in each member state before they become
available for patients, just like any other drugs. In England and Wales, the National In-
stitute for Health and Care Excellence (NICE) is responsible for undertaking HTA, with
the aim of ensuring equity in healthcare provision by the NHS. However, NICE’s tech-
nology assessment scheme is designed primarily for medicines targeting common dis-
eases. NICE has also developed a separate scheme for Highly Specialized Technology,
but this focuses on so-called ultra-rare diseases, while NICE’s administrative capacity to
run this scheme since its re-organization seems rather limited. For most orphan drugs,
a decision on whether to make them available to patients is left to the NHS, but pres-
ently no clear and transparent way of reaching this decision seems to exist.
Increasingly, the importance of early involvement of all relevant stakeholders in de-
velopment of drugs for rare diseases is being stressed. The EMA and COMP now en-
courage companies to engage at an early stage both with them and with patients, in
order to understand what kind of evidence of risks and benefits is required for obtain-
ing market authorization, and to design effective methods for collecting such evidence
among small and often widely scattered populations of rare disease patients. A similar
emphasis is visible in pilot efforts to coordinate post-market health technology assess-
ment and access processes across member states, for instance EUnetHTA and the
Mechanism of Coordinated Access to orphan medicinal products (MoCA). However,
while these efforts could potentially simplify the approval process and reduce the obsta-
cles that prolong waiting times for patients, concerns remain about their implications
for national decisions on health care provision and about potential inconsistencies –
particularly between regulators and HTA bodies – of risk-benefit assessment for market
and post-market authorization processes. Moreover, the politics of regulation and regu-
latory reform are complex and contentious, while the option of engaging in that polit-
ical arena may entail very considerable opportunity costs, particularly to small
organizations with limited resources.
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3. The opportunity costs for patient organizations need to be recognized
Patient organizations are not homogeneous. Some organizations have a longer history
than others, and some have access to more resources – in terms of both finance and
expertise – than others. Most patient organizations deploy their resources across a
range of arenas, addressing various aspects of the life of patients, including increasing
awareness about their disease, collecting and disseminating information about adequate
care, funding research projects and advocating for better health services. Identification
of a potentially effective medication can lead patient organizations to divert substantial
resources to support development of the drug in order to make it available for their pa-
tients as quickly as possible – but this often means sacrificing other important activ-
ities. The longer the drug development process takes, the more significant such
opportunity costs for patient organizations will be. Moreover, while umbrella organiza-
tions like EURORDIS and the Genetic Alliance UK provide support to smaller patient
organizations, not all organizations are equally capable of bearing the cost.
While patient organizations make every effort to reduce this impact on their overall
capacity, those efforts may be hindered by lack of clarity in regulatory or commission-
ing procedures, or by sudden changes in those procedures. For instance, such changes
may disrupt efforts to build on the experience of other organizations, particularly in
gathering the information necessary to secure approval for or access to new medicines.
Participants also reported cases where a patient organization was advised to fill out the
wrong forms or had to wait longer than promised for a response from the regulatory
authority or healthcare provider. Such disruptions greatly add to the opportunity costs
to patient organizations, as well as prolonging waiting times for patients in urgent need
of a drug. Much more care needs to be taken by regulatory authorities and healthcare
providers to minimize these costs to patient organizations, both when administering
established procedures and when introducing changes in procedure.
4. The role of patient-private partnerships in drug development needs to be
more clearly specified
It is patients who know best what it is like to live with their disease or condition. That
knowledge is invaluable, and is mobilized at many different stages of drug development
by different stakeholders – for example when patient organizations support and fund
the development of registries and natural history databases to manage and provide in-
formation about their members, both deceased and living, to help academics or com-
panies design and shape their research projects. Such active partnerships with
companies often proceed without problems in the pre-competitive stages of research
and development, but may run into problems in the later stages of drug development.
For instance, tensions may arise when more than one company becomes interested in
conducting clinical trials of a drug for a very small patient population. A concern was
also expressed about the risk of patient organizations associating too closely with part-
ner companies, particularly where a company provides financial support to the patient
organization or lists the organization as an advisor or consultant, as such links could
potentially be seen as entailing a conflict of interest when a patient organization is
asked to provide evidence for efficacy of the drug for approval or commissioning
purposes.
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Patient organizations are increasingly considered as valuable sources of evidence
throughout the process of drug development, but questions about how that evidence is
produced and valued remain underexplored. Regulators, HTA bodies and healthcare
providers often solicit evidence based on patients’ personal experiences that ‘brings to
life’ the disease or the condition that a drug is to treat. Some patient organizations have
developed skills in crafting and delivering such evidence, while pharmaceutical com-
panies also collect patients’ personal testimonies and submit them as a part of their
new drug applications along with more conventional clinical trials data on the clinical
benefits and risks of a drug. However, the precise role of such evidence in regulatory
and healthcare decision making, and the value of such evidence compared to clinical
trials data, remains unclear.
Some companies – mostly small- and medium-sized enterprises – have been better
at working with patient organizations than others, and moves are under way in the
United States to improve the quality of such interactions across the industry. In this
context, it is critical to understand what counts as a good interaction and how it would
benefit patients. One suggestion made in the workshop was that a clearer definition of
the contributions that patient organizations can make to drug development might in-
clude defining an appropriate legal mechanism to determine what kinds of compensa-
tion such organizations are entitled to – either as individual organizations or as
representatives of a larger patient community.
5. Discussions about rare diseases may need to reflect their changing relation-
ship with more common diseases
In 2013, the British Government published the UK Strategy for Rare Diseases [23]. This
Strategy resulted from intensive discussions among various stakeholders and hence
covers a broad range of areas that affect the lives of rare disease patients. Yet imple-
mentation proceeds slowly, while the rare disease landscape continues to change and
revisions may be required. In particular, the Strategy includes a commitment to develop
a transparent process for introducing new therapies. But translating that commitment
into an effective process has proved to be a challenge, and concerted effort by the NHS
is urgently needed. Some workshop participants suggested that re-framing this commit-
ment in relation to medicine more generally might help to make clear how important it
is. One reason for commercial investment in the development of certain innovative
medicines for rare diseases is because of expectations that those treatments, once suc-
cessfully developed, would subsequently be applicable to other diseases. At the same
time, genomic medicine is increasingly dividing common diseases into collections of
rare diseases. Consequently, any effective provision for introducing new therapies
would likely be more widely applicable than just to what are currently seen as rare
diseases.
One approach that has already been implemented, and that looks to offer a promising
way of sharing risks among key stakeholders and broadening accountability for drug
development, is the use of so-called Managed Access Programmes in the United King-
dom. In such a program, patients are given access to a new drug as part of a post-
marketing data collection effort, subject to pre-determined start and stop criteria
agreed by all the stakeholders including clinicians, the manufacturer, a patient
organization, NICE and the NHS. Access is promised for a pre-specified timeframe
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provided participating patients adhere to the treatment protocol and are judged to de-
rive benefit from it. The data thus collected are evaluated by NICE after this pre-
specified period when a final approval decision is taken. A similar approach has been
adopted for allocation of the Cancer Drugs Funds at the NHS, suggesting that expan-
sion of the scope of such programs to include both common and rare diseases may be
valuable.
6. The impact of the Brexit decision needs to be assessed and necessary mea-
sures taken
The workshop took place only a few days after the result of the referendum on UK
membership in the European Union was announced, and concern about the impact of
the Brexit decision on rare diseases surfaced repeatedly throughout the proceedings. In
Europe, rare diseases became recognized as a public health issue in the 1990s, primarily
in relation to integration of European pharmaceutical market [7]. EU policies on rare
diseases since then have had significant influence on the policy decisions of its member
states, as exemplified by the UK Strategy for Rare Diseases, which was produced to
comply with the 2009 recommendation of the Council of the European Union [24].
The Brexit decision may potentially impact on the regulation of medicines, on pharma-
ceutical and biotechnology companies, and on practical arrangements for research and
clinical collaboration – all of which relate, in one way or another, to the issues dis-
cussed at this workshop. The decision raises a host of uncertainties which need to be
monitored and appropriate and timely measures taken, particularly where negative im-
pacts are expected.
Conclusions
Although rare disease patient organizations strive to secure access to the drugs that pa-
tients need, the resources available to them to do so are limited. Consequently, in order
to achieve economies and synergies, it is important that patient organizations work as
far as possible in partnership, not just with one another, but also with other stake-
holders, including companies, regulators, healthcare professionals, politicians and aca-
demics. However, it became apparent in the course of this workshop that partnership
working can entail risks as well as benefits.
“Partnership” can mean different arrangements to different stakeholders – not all
partners are equal, and some may be better positioned to define the terms of partner-
ship than others. Rare diseases patients may be in a particularly weak position because
of the small size of their community. Some patient organizations may afford to invest
their resources in making the partnership work, but it should be recognized that they
are the exceptions, rather than the rule. The issues identified in the workshop reflected
the facts that partnership – be it with private companies or with regulatory agencies or
HTA bodies – often involves compromise and that establishing an effective and mutu-
ally beneficial partnership can be a significant challenge to many. Also, as one partici-
pant pointed out during the workshop, partnership is not an answer in itself – that is,
it does not necessarily lead to access to medicines. While good intentions and mutual
respect are valuable, the ‘rightness’ of any partnership therefore needs to be assessed in
terms of whether it helps to attain that goal.
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The policy-engagement workshop format provided a valuable setting in which to ex-
plore these issues. Most workshop participants were familiar with at least some of these
issues from their past experiences, but had not necessarily recognized them as systemic
issues needing to be addressed at the societal level. In a field populated by many, rela-
tively small organizations, there is often a tendency to adopt a local, particularistic view
of the challenges one faces, and to regard success or failure as a matter of the particular
skills, resources and opportunities each organization is able to mobilize – as a matter
of how well one can ‘play the game.’ The workshop provided an opportunity for the
participants to share their experiences in a safe space, and to get a more systematic
view of how the particular challenges they face are framed and structured – how, in
other words, the ‘rules of the game’ are themselves determined, and what sorts of mea-
sures may be needed to revise those rules in ways more favorable to the needs of rare
disease patients.
This report presents some of the main observations to emerge from that workshop.
It focuses on issues where a degree of common ground was established, in the expect-
ation that this will provide a basis for further debate and action, not confined to the in-
dividuals and organizations that participated in the workshop itself. We did not
undertake a formal evaluation of the impact of the policy-engagement workshop on the
participants, chiefly because the process of engagement was expected to continue with
the drafting, redrafting and approval of this report. However, we take the continued in-
volvement of the participants in the production of this report, and their willingness to
see it published, as an indication that, at minimum, the workshop provided an oppor-
tunity to air and publicize certain issues that they consider worthy of wider attention.
In particular, we note that while the workshop focused on challenges encountered spe-
cifically in relation to rare diseases, the consensus among the participants was that the
issues identified will also become relevant to more common diseases, particularly due
to advances in genomic technology. Consequently, the dialogue started at the workshop
needs to be expanded, not just to involve other rare disease patient organizations, but to
wider patient communities – including in particular the growing community of rare can-
cer organizations. Given the design of our workshop, we have no intention of claiming
that it offers an answer to the complex problems and challenges that it explored, We
would hope, however, that the workshop, and this report, might mark the beginning, not
the end, of an expanding process of multi-stakeholder discussion and action around the
problems of securing access to treatment to a growing number of rare diseases.
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